[go: up one dir, main page]

WO2019004868A3 - Combination of a chondroprotective agent with an nsaid - Google Patents

Combination of a chondroprotective agent with an nsaid Download PDF

Info

Publication number
WO2019004868A3
WO2019004868A3 PCT/RU2018/000345 RU2018000345W WO2019004868A3 WO 2019004868 A3 WO2019004868 A3 WO 2019004868A3 RU 2018000345 W RU2018000345 W RU 2018000345W WO 2019004868 A3 WO2019004868 A3 WO 2019004868A3
Authority
WO
WIPO (PCT)
Prior art keywords
nsaid
combination
chondroprotective agent
osteoarthritis
chondroprotective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2018/000345
Other languages
French (fr)
Russian (ru)
Other versions
WO2019004868A2 (en
Inventor
Алексей Валерьевич ЧЕКАЛОВ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Obshchestvo S Ogranichennoy Otvetstvennostyu "fbk"
Original Assignee
Obshchestvo S Ogranichennoy Otvetstvennostyu "fbk"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obshchestvo S Ogranichennoy Otvetstvennostyu "fbk" filed Critical Obshchestvo S Ogranichennoy Otvetstvennostyu "fbk"
Publication of WO2019004868A2 publication Critical patent/WO2019004868A2/en
Publication of WO2019004868A3 publication Critical patent/WO2019004868A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un médicament peroral contenant diacéréine, chondroïtine et glucosamine et son utilisation dans le traitement de l'ostéoarthrite, des articulations périphériques, de l'ostéochondrite intervertébrale, de l'ostéoarthrite et de l'ostéoporose, de la parodontopathie et/ou pour accélérer la formation d'un cal osseux lors de fractures.The invention relates to a peroral drug containing diacerein, chondroitin and glucosamine and its use in the treatment of osteoarthritis, peripheral joints, intervertebral osteochondritis, osteoarthritis and osteoporosis, periodontal disease and / or to accelerate the formation of bone callus during fractures.

PCT/RU2018/000345 2017-06-30 2018-06-28 Combination of a chondroprotective agent with an nsaid Ceased WO2019004868A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2017123275 2017-06-30
RU2017123275A RU2742172C2 (en) 2017-06-30 2017-06-30 Combination of a chondroprotective agent with an nsaid

Publications (2)

Publication Number Publication Date
WO2019004868A2 WO2019004868A2 (en) 2019-01-03
WO2019004868A3 true WO2019004868A3 (en) 2019-02-07

Family

ID=64184153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2018/000345 Ceased WO2019004868A2 (en) 2017-06-30 2018-06-28 Combination of a chondroprotective agent with an nsaid

Country Status (2)

Country Link
RU (1) RU2742172C2 (en)
WO (1) WO2019004868A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198695A1 (en) * 2003-04-02 2004-10-07 Anhu Li Joint-protecting beverages and/or foods and their preparations
WO2009065604A2 (en) * 2007-11-23 2009-05-28 Bayer Consumer Care Ag Pharmaceutical composition comprising glucosamine sulfate, chondroitine sulfate and ibuprofene
WO2010109256A1 (en) * 2009-03-23 2010-09-30 Carlo Ghisalberti Enhanced treatment of joint and connective tissue damage
EP2243478A1 (en) * 2007-09-26 2010-10-27 World Trade Import-Export, WTIE A.G. Pharmaceutical composition combining an antiarthritic agent and an interleukin-1 inhibiting agent, which can be used to control and treat osteoarthritis and related diseases
WO2013100882A2 (en) * 2011-12-27 2013-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Combinations of diacerein and non-steroidal inflammation drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2478376C1 (en) * 2011-11-24 2013-04-10 Общество С Ограниченной Ответственностью "Консорциум-Пик" Pharmaceutical composition based on vegetative dha for treating and preventing diseases of joints

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198695A1 (en) * 2003-04-02 2004-10-07 Anhu Li Joint-protecting beverages and/or foods and their preparations
EP2243478A1 (en) * 2007-09-26 2010-10-27 World Trade Import-Export, WTIE A.G. Pharmaceutical composition combining an antiarthritic agent and an interleukin-1 inhibiting agent, which can be used to control and treat osteoarthritis and related diseases
WO2009065604A2 (en) * 2007-11-23 2009-05-28 Bayer Consumer Care Ag Pharmaceutical composition comprising glucosamine sulfate, chondroitine sulfate and ibuprofene
WO2010109256A1 (en) * 2009-03-23 2010-09-30 Carlo Ghisalberti Enhanced treatment of joint and connective tissue damage
WO2013100882A2 (en) * 2011-12-27 2013-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Combinations of diacerein and non-steroidal inflammation drugs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
E. TROFIMOV ET AL: "The effect of different treatments on the clinical course of knee osteoarthritis", OSTEOARTHRITIS AND CARTILAGE., vol. 26, 1 April 2018 (2018-04-01), GB, pages S306 - S307, XP055530990, ISSN: 1063-4584, DOI: 10.1016/j.joca.2018.02.617 *
R MIRUNALINI ET AL: "EFFICACY OF CHONDROITIN SULFATE WITH GLUCOSAMINE VERSUS DIACEREIN IN GRADE II AND III OSTEOARTHRITIS KNEE: A RANDOMIZED COMPARATIVE STUDY", ASIAN JOURNAL OF PHARMACEUTICAL AND CLINICAL RESEARCH : AJPCR, vol. 8, no. 4, 1 January 2015 (2015-01-01), IN, pages 244 - 246, XP055530976, ISSN: 0974-2441 *
STEINMEYER J ET AL: "Oral treatment options for degenerative joint disease-presence and future", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 58, no. 2, 20 May 2006 (2006-05-20), pages 168 - 211, XP024892181, ISSN: 0169-409X, [retrieved on 20060520], DOI: 10.1016/J.ADDR.2006.01.007 *

Also Published As

Publication number Publication date
RU2742172C2 (en) 2021-02-02
RU2017123275A (en) 2019-01-09
WO2019004868A2 (en) 2019-01-03
RU2017123275A3 (en) 2019-01-09

Similar Documents

Publication Publication Date Title
EP4529952A3 (en) Parp1 inhibitors
EP3809988C0 (en) OCCLUSIONS TREATMENT SYSTEM IN BODY LIGHTS
BR112015022634A2 (en) embolisation systems
EP4410832A3 (en) Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
EP3193824C0 (en) COMPOSITION FOR ITS USE IN THE TREATMENT OF HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA THROUGH PHYSIOLOGICALLY SYNTHESIZED GLUTATHIONE
MA33231B1 (en) BIOVERRE-BASED MACROPOROUS CEMENTS, BIOACTIVE, BIORESORBABLE FOR BIOMEDICAL USE
EP2985281A3 (en) Isoindoline compounds for use in the treatment of cancer
EP2497465A3 (en) Gastroretentive system with alginate body
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2018071741A8 (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
HK1253734A1 (en) Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease
EP3059254A3 (en) A sulphated polysaccharide compound for the clinical use and the preparation and use thereof
EP3606570B8 (en) Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds
EP4008718C0 (en) HETEROARYLAMIDOPYRIDINOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR THE PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES
CN106572870A8 (en) Flexible maxillary fixation device
WO2019004868A3 (en) Combination of a chondroprotective agent with an nsaid
EP3398614A4 (en) AGENT FOR THE PREVENTION AND / OR TREATMENT OF ALZHEIMER'S DISEASE
EP3650029A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY, CONTAINING AN ADENOSINE DERIVATIVE
MA54936A (en) TRIAMTERENE OR NOLATREXED FOR USE IN THE TREATMENT OF PHENYLKETONURIA
HK1247558A1 (en) Cenicriviroc for the treatment of fibrosis
EP3785718A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AN INFECTIOUS FLAVIVIRUS DISEASE
EP4052694A4 (en) COMPOSITION OF EYE DROPS FOR THE PREVENTION OR TREATMENT OF EYE DISEASE
MA52438A (en) STERILE OR STERILIZED PACKAGING FOR THE ADMINISTRATION OF MEDICINAL OR NUTRITIONAL SUBSTANCES.
EP4062844A4 (en) ENDOSCOPIC CAP, ENDOSCOPIC TREATMENT TOOL AND ENDOSCOPE SYSTEM
EP3344071A4 (en) COMBINED COMPOSITIONS FOR REGULATING GLYCEMIA LEVELS, HEPATOPROTECTION, AND FOR THE PREVENTION AND TREATMENT OF ASSOCIATED MEDICAL CONDITIONS

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 17.06.2020)

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18799879

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 18799879

Country of ref document: EP

Kind code of ref document: A2